Synonym
CI-898 HCl; CI898 HCl; CI 898 HCl; CI-898 hydrochloride, Trimetrexate trihydrochloride
IUPAC/Chemical Name
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine, trihydrochloride
InChi Key
ZNJRHEVYOYMEHR-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23N5O3.3ClH/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;;;/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3*1H
SMILES Code
COC1=C(OC)C(OC)=CC(NCC2=C(C)C(C(N)=NC(N)=N3)=C3C=C2)=C1.Cl.Cl.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
478.80
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Sasso, S.P., Gilli, R.M., Sari, J.C., et al. Thermodynamic study of dihydrofolate reductase inhibitor selectivity. Biochim Biophys. Acta. 1207(1), 74-79 (1994).
2. Hook, K.E., Nelson, J.M., Roberts, B.J., et al. Cell cycle effects of trimetrexate (CI-898). Cancer Chemother. Pharmacol. 16(2), 116-120 (1986).
3. Elslager, E.F., Johnson, J.L., and Werbel, L.M. Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines. J. Med. Chem. 26(12), 1753-1760 (1983).
4. Allegra, C.J., Kovacs, J.A., Drake, J.C., et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J. Clin. Invest. 79(2), 478-482 (1987).
5. Leopold, W.R., Dykes, D.J., and Griswold, D.P., Jr. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. NCI. Monogr. 5, 99-104 (1987).
